CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 51 enrolled
Drug / intervention
Ferrous Sulfate 300Mg Tablet +1 moredrug
Likely dose
Ferrous Sulfate 300Mg Tabletfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03725384
NCT03725384Phase 3Completed

Daily vs. Every Other Day Oral Iron Supplementation in Patients With Absolute Iron Deficiency Anemia (DEODO): a Multi-centered, Pilot Randomized Controlled Trial

Sunnybrook Health Sciences Centre·interventional·Posted Oct 31, 2018·Updated Feb 3, 2025

In Brief

A Phase 3 clinical trial evaluating Ferrous Sulfate 300Mg Tablet and Vitamin C 500Mg tablet for Anemia and Iron Deficiency Anemia. Completed, enrolled 51 participants across 2 sites.

Detailed Summary

Iron deficiency anemia is a global health problem and the most common cause of anemia worldwide. Patients with iron deficiency (ID) and IDA can present with a multitude of symptoms including fatigue, restless legs syndrome and pica.Oral iron supplementation is associated with increasing hemoglobin in multiple studies in women, pregnant women and elderly patients.However, the optimal dose and frequency of oral iron supplementation for treatment remains unclear. The current proposed study attempts to address this gap in the literature.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesCanada

Timeline

Phase 3CompletedFinished
20192020202120222023202420252026
First PostedOct 31, 2018
Enrollment StartJan 4, 2019
Primary CompletionJan 26, 2022
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 7.7 years ago

Interventions

Ferrous Sulfate 300Mg Tabletdrug

oral dose of Ferrous Sulfate (300 mg) every day versus every other day along with vitamin C

Vitamin C 500Mg tabletdrug

Vitamin C 500 Mg tablet every day versus every other day along with ferrous sulfate